MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/neuros/nyaa478

Медицинская библиотека · Neurosurgery · 2021

A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH).

Girard Romuald, Li Yan, Stadnik Agnieszka, Shenkar Robert, Hobson Nicholas, Romanos Sharbel, Srinath Abhinav, Moore Thomas, Lightle Rhonda, Shkoukani Abdallah, Akers Amy, Carroll Timothy, Christoforidis Gregory A, Koenig James I, Lee Cornelia, Piedad Kristina, Greenberg Steven M, Kim Helen, Flemming Kelly D, Ji Yuan, Awad Issam A

СтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

BACKGROUND

Cerebral cavernous angioma (CA) is a capillary microangiopathy predisposing more than a million Americans to premature risk of brain hemorrhage. CA with recent symptomatic hemorrhage (SH), most likely to re-bleed with serious clinical sequelae, is the primary focus of therapeutic development. Signaling aberrations in CA include proliferative dysangiogenesis, blood-brain barrier hyperpermeability, inflammatory/immune processes, and anticoagulant vascular domain. Plasma levels of molecules reflecting these mechanisms and measures of vascular permeability and iron deposition on magnetic resonance imaging are biomarkers that have been correlated with CA hemorrhage.

OBJECTIVE

To optimize these biomarkers to accurately diagnose cavernous angioma with symptomatic hemorrhage (CASH), prognosticate the risk of future SH, and monitor cases after a bleed and in response to therapy.

METHODS

Additional candidate biomarkers, emerging from ongoing mechanistic and differential transcriptome studies, would further enhance the sensitivity and specificity of diagnosis and prediction of CASH. Integrative combinations of levels of plasma proteins and characteristic micro-ribonucleic acids may further strengthen biomarker associations. We will deploy advanced statistical and machine learning approaches for the integration of novel candidate biomarkers, rejecting noncorrelated candidates, and determining the best clustering and weighing of combined biomarker contributions.

EXPECTED OUTCOMES: With the expertise of leading CA researchers, this project anticipates the development of future blood tests for the diagnosis and prediction of CASH to clinically advance towards precision medicine.

DISCUSSION: The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease with a relevant context of use, with an approach applicable to other neurological diseases with similar pathobiologic features.

Для цитирования: Girard Romuald, Li Yan, Stadnik Agnieszka, Shenkar Robert, Hobson Nicholas, Romanos Sharbel, Srinath Abhinav, Moore Thomas, Lightle Rhonda, Shkoukani Abdallah, Akers Amy, Carroll Timothy, Christoforidis Gregory A, Koenig James I, Lee Cornelia, Piedad Kristina, Greenberg Steven M, Kim Helen, Flemming Kelly D, Ji Yuan, Awad Issam A. A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH).. Neurosurgery. 2021. DOI: 10.1093/neuros/nyaa478.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.